Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amiloride is a potassium-sparing diuretic used primarily in combination with other diuretics to treat hypertension (high blood pressure), congestive heart failure, and edema, especially in patients at risk of low potassium levels. It acts by directly blocking the epithelial sodium channel (ENaC) in the distal convoluted tubule, connecting tubule, and collecting duct of the nephron. This inhibition reduces sodium reabsorption and promotes excretion of sodium and water while minimizing potassium loss. Amiloride is not an aldosterone antagonist; its effects are independent of aldosterone presence. The drug may also inhibit Na+/H+ exchangers such as NHE-1 on cardiac tissue and has some action on acid-sensing ion channels (ASICs). It is administered orally as a tablet[1][2][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amiloride.